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Abstract 
Oral cavity Squamous Cell Carcinoma (OSCC) is a common form of head and neck cancer 
through the developed and developing world. Tobacco exposure is a significant risk factor in 
the aetiology of OSCC, however 20% of these cancers occur in a non-smoking population. 
There have been multiple suggestions as to the causation of these cancers in the non-smoking 
population, including the human papilloma virus (HPV) and chronic dental trauma. The 
evidence on HPV has been divided, clouded by experimental design, differing methods of 
HPV detection, small study populations and inclusion of data from oropharyngeal SCC in the 
study population. There has been limited evidence exploring the role of chronic dental trauma 
in the aetiology of OSCC. This project sought to explore the aetiology of oral cavity cancers, 
by exploring the genetic and transcript differences in a population of OSCCs collected from 
Brisbane Head and Neck Clinics between 2013 to 2015.  
 
Following participant recruitment and informed consent, a fresh tissue biopsy was taken from 
each individual, either at the time of diagnosis, or at the time of surgical treatment.  DNA and 
RNA extraction was performed on the fresh tissue. Extracted DNA from 14 samples were 
tested using the HC2 High-Risk HPV test kit, to attempt to identify HPV in the tissue. 
However, none of the 14 samples tested positive with the HC2 kit. The OSCC samples were 
tested using PCR, with both a generic HPV primer (MY11/09) and a HPV16 specific primer. 
From these 14 samples that were taken, none showed the presence of HPV16, with only one 
sample having the potential presence of a low risk HPV present.  
 
As there was no conclusive evidence suggesting high-risk HPV plays a significant role in the 
aetiology of OSCC from the HC2 or PCR testing performed, this study progressed to DNA 
exome sequencing and RNA sequencing. The RNAseq data was first explored to understand 
the RNA transcriptome. Following mapping of the RNAseq data to the human genome, this 
study then mapped the RNAseq data to the HPV genome to attempt to identify HPV presence 
in the transcriptome. Only two samples were HPV16 positive (4.54%). These samples 
showed high expression of E6 and E7, indicating that HPV16 was a likely contributing factor, 
if not a causative factor in these two samples. Both of these samples were however from 
current smoking participants.  
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A principal component analysis (PCA) attempted to explore whether the samples, when 
arranged by the principal variance components, would cluster based upon the demographics 
collected. This study utilised the PCA to determine whether the smoking status, tumour stage 
and tumour location of the participant would reveal clustering of samples based on the RNA 
transcriptome. None of these demographic factors showed significant clustering, based on an 
80% confidence interval. A Weight Gene Co-expression Network Analysis (WGCNA) 
analysis was performed, to attempt to identify whether transcriptome differences could be 
explained by the demographic details that were collected. Overall, more advanced disease 
showed transcriptome changes consistent with the Warburg effect. Tumours from smoking 
participants showed a non-significant trend towards increased m-TOR signalling, TLR4 
signalling and EGF-EGFR signalling. This may potentially be of use in future therapeutic 
development.  
 
DNA exome analysis was then completed. Interpretation followed the procedure outlined by 
the Broad Institute’s GATK Best Practice Workflow. As there was no matched normal tissue 
from the participants, data from the 1000 genomes project was used to help identify common 
germline variants. Utilising the GenVisR package, commonly mutated genes in the data set 
were visualised. Genes that were frequently mutated were genes commonly associated with 
SCCs, especially TP53. Other genes commonly mutated in the data set include HUWE1 and 
CDKN2A.  
 
There is significant future work that may be completed as a result of this research. If this 
study was repeated, matched normal tissue would be collected, to help eliminate germline 
variants as a confounding factor of the sample analysis. Further demographic data may assist 
in explaining some the driving aetiology and may allow exploration of other factors, such as 
survival. Finally, with increasing next-generation sequencing being performed, both in 
Australia and around the world, collaborations between different head and neck centres 
would allow increased participant numbers, enabling detection of subtle differences between 
sub-groups, which may help with development of personalised therapeutics in the future.  
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1.0	Introduction	
 
Head and Neck Cancers (HNC) are a significant cause of morbidity and mortality in both the 
developed and developing world. Every year, more than 500,000 people are diagnosed with 
HNC 1. HNC are classified by both their anatomical location and their histology. One of the 
common types of HNC is Oral Cavity Squamous Cell Carcinoma (OSCC). There are 
numerous risk factors that have been implicated in the oncogenesis of OSCC, the most 
significant being tobacco and alcohol consumption. However, recently there has been an 
increasing number of OSCCs appearing in younger populations who have had less significant 
tobacco exposure. Several different explanations have been suggested for the cause of the 
cancers in these populations, however there is yet to be conclusive evidence of the factors 
leading to OSCC. 
	
Oral	Cavity	Cancers	
The definition of the oral cavity varies between studies 2. The majority of studies consider 
lips, tongue (anterior to the terminal sulcus), upper and lower gingiva, floor of mouth, hard 
palate, cheek mucosa, vestibule of mouth, retromolar trigone and major salivary glands as 
part of the oral cavity. OSCC has been primarily diagnosed in patients between the age of 50-
69, with a reported median age of diagnosis of 64 3, 4. Males account for 60% of OSCC 
patients 3.  
 
Tobacco smoking represents perhaps the most significant risk factor for the development of 
OSCC 2. A systematic review of the literature by Radoï et al. reviewed over 100 articles in 
relation to the risks of developing HNC and OSCC 2. Radoï concluded that risk of developing 
OSCC in smokers was 1.4-1.7 times higher than in the non-smoking population 2. Case 
control studies have demonstrated that the risk of developing OSCC was linked to the 
frequency of smoking 5 and duration of smoking 2, 5. Radoï et al. implicated that 18% of 
OSCCs were attributable to alcohol consumption 2. Similar to tobacco exposure, the risk of 
OSCC following alcohol consumption appears to follow a dose-response relationship 2, and 
additionally frequently heavy alcohol consumption was linked with heavy tobacco exposure, 
further compounding the carcinogenic effect.   
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While well-known risk factors, such as tobacco and alcohol exposure, explain the majority of 
OSCCs, there remains a subset in a non-drinking, non-smoking population. A study 
published in Brisbane, Australia found that over 20% of OSCCs occurred in a non-smoking 
population. These non-smoking tumours were found to be more frequently located at sites of 
chronic dental trauma and were common in a younger cohort 6 
 
Multiple risk factors, other than tobacco and alcohol exposure have been proposed as a 
causative agent for carcinogenesis in the oral cavity, and significantly these include chronic 
dental trauma and the Human Papilloma Virus (HPV). Additionally with the advent of new 
sequencing technology, increasingly there is further work involving exploring the genome 
and transcriptome for potential causes of HNC in different populations.  
 
A literature search was used to identify all articles investigating these factors in the aetiology 
of oral cavity cancer. The search terms used were: (Oral Cavity Cancer OR OSCC) AND 
(Chronic dental trauma OR Broken tooth OR Dental Trauma OR Oral Hygiene OR Tooth OR 
Non-smokers) NOT (Radiotherapy OR Osteoradionecrosis OR Osteonecrosis). These search 
terms were chosen to identify any relevant article pertaining to the topic of chronic dental 
trauma. Once excluding articles that were not in humans or weren’t written in English, there 
were 984 articles identified. However, due to the broad search terms used, many articles 
remained were not applicable to the topic being studied. Overall, only ten articles were 
identified investigating the role of chronic dental trauma and OSCC. Table 1 outlines the 
major studies analysed with respect to chronic dental trauma. 
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Table 1 –Articles Reviewed on the topic of Chronic Dental Trauma 
Article Sample 
Size 
Risk 
Factor 
Analysed 
Conclusion 
Thumfart et al 7 86 Chronic 
dental 
trauma 
Cohort Study. 44% of OSCC had history of 
chronic mechanical trauma. 
Velly et al 8 2,151 Chronic 
dental 
trauma 
Case Control Study. History of oral sores with 
dentures risk of developing OSCC (OR 2.3 (95% 
CI 1.2-4.6)). 
Koch et al 9 305 Smoking 
status and 
tumour 
location 
Cohort Study. Smoking patients – more likely to 
have tumour on floor of mouth. Non-smokers 
more likely to have tumour on tongue. Non-
smoking population generally younger. 
Lockhart et al 10 99 Chronic 
Dental 
Trauma 
Case Control Study. Of all head and neck cancers, 
100% of OSCC occurred in areas in contact with 
teeth or dental appliances.  
Abrams & 
Sadeghi 11 
1 Chronic 
Dental 
Trauma 
Case Study. Oral lingual papilloma arising in 
presence of chronic dental trauma. 
Behnoud, 
Torabian & 
Zargaran 12 
64 Chronic 
Dental 
Trauma 
Cohort Study. No significant difference in 
likelihood of having broken teeth, dentures or 
dental decay. However trending towards possible 
link between dental trauma and OSCC.   
Bundgaard, 
Wildt & Elbrond 
13 
161 Smoking 
status and 
tumour 
location 
Case Control Study. Non-smoking tumours were 
most likely to occur on the tongue compared with 
any other region. OSCC still more likely to occur 
in smoking population.  
Dahlstrom et al  
14 
1,302 Smoking 
status and 
tumour 
location 
Cohort Study. Non-smoking patients more likely 
to develop cancer on the tongue, compared with 
other head and neck cancer sites. Non-smokers 
typically younger cohort.  
Piemonte, Lazos 
& Brunotto 15 
406 Chronic 
Dental 
Trauma 
Case Control Study. Significantly increased 
likelihood of having chronic trauma of oral 
mucosa amongst the OSCC population compared 
with a normal cohort.  
Perry et al 6 881 Smoking 
status and 
tumour 
location 
Cohort Study. Non-smoking patients more likely 
to develop cancer at sites of chronic dental trauma 
compared with smoking patients. Non-smokers 
typically younger and female.  
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There were a significantly larger number of publications on the role of HPV in the aetiology 
of OSCC. The search terms used to collect appropriate articles were: (Oral Cavity Cancer OR 
OSCC) AND (Human Papilloma Virus OR HPV). Once articles that were not in English and 
were not in humans were excluded there were 610 articles identified. Following review of 
these articles, 99 were identified as being relevant to the discussion of whether HPV plays a 
role in the oncogenesis of OSCC. Eleven of these were systematic reviews or meta-analyses. 
There was a single case report. Of the remaining articles (n=85), all being original research, a 
wide variety of different techniques were used to detect HPV and HPV induced disease in the 
tissue. Table 2 outlines the different techniques and the studies that used each technique. 
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Table 2 – Techniques Used to Detect HPV in OSCC 
Technique Number of 
Studies 
using this 
Technique 
Rate of HPV 
Induced Disease 
(Range) 
Studies 
Using This 
Technique 
Single Technique 
 ELISA 1 E6=30% E7=18% 16 
Histology 1 73.3% 17 
HPV Antibodies 1 4.5% 18 
Immunohistochemistry (excluding P16) 1 86.6% 19 
INNO-Lipa Assay 1 10.5% 20 
In-situ hybridisation 2 9.1-24% 21, 22 
Linear Array 1 4% 23 
P16 1 86.6% 24 
Polymerase Chain Reaction (PCR) 46 0-100% 25-71 
Real Time –PCR (RTPCR) 1 2% 72 
Southern Blot 1 65% 73 
Multiple Techniques 
 Clinichip, ISH & Immunohistochemstry 
(P16) 
1 Clinichip: 0% 
P16: 19% 
74 
ISH & P16 1 ISH: 1.3-37% 
P16: 11.5-21.5% 
75, 76 
PCR & 3 different commercial tests 1 71.9% 77 
PCR & ELISA 3 0-26.1% 78-80 
PCR & HC2 1 32.4% 81 
PCR & Immunohistochemistry 2 PCR: 5-33.3% 
pRb: 72.72% 
p53: 32.5% 
p16: 15% 
82, 83 
PCR, Immunohistochemistry & ISH 3 PCR: 0-48%  
IHC: 8-33% 
ISH: 4-67% 
84-87 
PCR & ISH 1 0% 88 
PCR & P16 4 PCR: 0-56% 
P16: 16-56% 
89-93 
PCR, P16 & ISH 2 PCR: 9.6-25.1% 
P16: 5.8-18.9% 
ISH: 0-26.3% 
94, 95 
PCR & RNA expression 1 PCR: 3-11.3%% 
RNA: 0-9.4%  
87, 96 
PCR & RTPCR 2 36.6-47.7% 
(HPV16 most 
common subtype) 
97, 98 
RTPCR & ISH 1 PCR: 11.86% 
ISH: 0% 
99 
RTPCR & P16 1 RTPCR: 5.9% 
P16: 79% 
100 
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Table 2 illustrates there were a large number of articles published and the variety of 
techniques used to identify the presence of HPV in the tissue. The reported rate of HPV 
induced OSCC ranged in these studies from 0-100%. Additionally, a variety of techniques 
were employed to identify HPV induced disease. By far the most common was Polymerase 
Chain Reaction (PCR) with 73 of the 85 studies using some form of PCR (86%). When 
pooling the data from studies that utilised PCR and Real-Time PCR (RTPCR) as a method of 
detection, the mean incidence of HPV positive OSCCs was 24.0% (18.3-29.6%). The median 
reported rate of HPV prevalence was 24%.  If those utilising RTPCR were excluded, the 
mean rate of HPV presence was 25.5% (19.6-31.4%). As shown in the table, there was high 
inter-study variability, with similar studies using similar detection techniques reporting 
presence of HPV from 0-100%. From the studies that further typed the HPV virus, the most 
common type reported was HPV16 18, 20, 27-30, 35-37, 94, 96, 97, 100. 
The next phase of this investigation into the cause of oral cavity cancer was to interrogate the 
literature to understand the genetic and genetic expression changes which may be implicated 
in oral cavity cancer. In 2001, the human genomic sequence was published 101. From this 
seminal research, extensive work has gone into exploring the genetic changes present within 
cancer tissue. Technological advances have now allowed researchers to rapidly and 
accurately assess the underlying genetic elements within a variety of different cancers, by 
utilising technology known as Next-Generation Sequencing (NGS). NGS has so far been 
utilised in only a limited number of studies exploring HNC. A literature search of “Oral 
cavity cancer” AND “Next-generation sequencing” through Pubmed, returned 42 results in 
July 2016. Of these seven publications were relevant to this research. Likewise for 
oropharyngeal studies, there were 13 results returned in a Pubmed literature search, however 
only three articles were of interest to this study. Finally when search for head and neck cancer 
studies utilising NGS, 212 results were returned in Pubmed, with 13 relevant articles to this 
investigation.  
 
Discussion	of	current	literature		
Oral Squamous Cell Cancer (OSCC) remains a growing issue throughout the developed and 
developing world.  
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Table 1 outlines all studies that have investigated the lesser-known carcinogen of chronic 
dental trauma. Overall there is minimal literature evidence to support chronic dental trauma 
as a potential oral carcinogen. The chronicity of the trauma along with the subjective nature 
of describing dental abnormalities may play a role in the lack of identification of it as a 
possible carcinogen. Additionally, OSCC has a relatively low incidence in Western 
populations making high-powered study design difficult. The majority of studies are a cohort 
or case-control studies, illustrating the difficulty in research design investigating dental 
trauma in oral cancers. Also, many studies were qualitative in nature, simply reporting trend 
in that cohort. Two of the more recent studies published both had performed cohort studies 
investigating tumour location relative to smoking status 6, 14. These studies found that in the 
non-smoking population, tumours were more likely to occur at sites of possible dental trauma, 
compared to a more widespread distribution in the smoking population. This minimised the 
reporting bias of relying on a clinician to describe potential dental trauma.  
 
Of interest, these two studies also reported that non-smoking tumours that occurred at sites of 
chronic dental trauma were more likely to occur in a younger population 6, 14 and, as reported 
by Perry et al, more commonly in the female population. Overall, these studies suggest that 
dental trauma plays a role in the aetiology of OSCC. The significance of this role is yet to be 
elucidated and further research is required to gain a better understanding of the link between 
OSCC and chronic dental trauma.  
 
Table 2 outlines the studies published investigating the link between the human papilloma 
virus (HPV) and the development of OSCC. HPV has been well documented as a cause of 
oropharyngeal squamous cell carcinoma (OPSCC), particularly in the non-smoking 
population 102, 103. Therefore, a potential link with non-smoking OSCCs is entirely plausible. 
The reported rate of HPV induced OSCC varied considerably in these studies from 0-100%. 
Analysis of HPV induced carcinogenesis has proven difficult. The most common method has 
been PCR amplification of HPV DNA. This allows researchers to identify HPV presence, but 
not whether HPV is responsible for carcinogenesis. When the data was pooled from studies 
using PCR, the rate of HPV induced disease was 24%. Whilst some may argue this represents 
the rate of HPV induced disease in the oral cavity, this actually only represents the rate of 
HPV presence alone, and not HPV induced carcinogenesis. There have been multiple other 
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techniques utilised to show HPV indicate carcinogenesis such as: in situ hybridisation 
(identifies HPV localising to the cell nuclei) 104, HPV serum antibodies (proving prior HPV 
infection, but not carcinogenesis) and E6/E7 oncogenes, which are produced by HPV. The 
difficulty with using E6 and E7 analysis is that it is costly in resources and time, therefore a 
surrogate for E6 and E7 has been developed. Cyclin Dependent Kinase Inhibitor 2A 
(CDKN2A), also known as p16, can be used as a surrogate for E7 inhibition of pRb 
functioning on E2F 105. With increased E7, and consequently lowered E2F-pRB, there is 
reduced negative feedback on the CDNK2A gene. This leads to an over-expression of p16, 
which can be identified using immunohistochemistry. However several of the articles, which 
utilised the P16 immunohistochemistry marker, noted a lack of correlation between PCR 
positivity and P16 positivity in the oral cavity 90, 95, 100. This is in contrast to the utility of 
utilising P16 immunohistochemistry in the oropharynx as a surrogate of HPV induced disease. 
Thus P16 immunohistochemistry staining in the oral cavity may not represent an accurate 
measure of HPV induced carcinogenesis.  
 
The variety of techniques utilised may explain the wide variation of reported rates of HPV 
induced OSCC. As previously mentioned, PCR, which was the predominant method used to 
identify HPV, only detects the presence of HPV in the tissue. It does not indicate that 
carcinogenesis is due to HPV, or even whether the HPV genome has been integrated into the 
host genome. Therefore, the high rates of HPV reported in the tissue with PCR may simply 
represent HPV presence, but not carcinogenesis. Overall, few studies went further to show 
that HPV had migrated to the nucleus and had been integrated into the genome, an essential 
step in carcinogenesis 74, 75, 84-86, 96. Overall those that analyse the rate of HPV migration 
and/or integration, generally showed a lower rate of HPV induced disease.  
 
Many studies were also performed retrospectively, potentially increasing bias in terms of 
sample selection and may have contributed to the large variability of reported HPV induced 
carcinogenesis. Finally, the definition of oral cavity is not uniform throughout the literature. 
Several studies report oral cavity as including the base of tongue. The base of tongue is a 
known anatomical region of the oropharynx, and is one of the commonest areas to find HPV 
induced OPSCC. Thus the inclusion of base of tongue tumours in the analysis of OSCC, may 
contribute to higher rates of reported HPV induced disease in the oral cavity.  
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Overall the literature generally suggests that there is a role of HPV induced disease in the oral 
cavity, however the inter-study variability is high making assessment of the true incidence 
difficult. Additionally PCR is the most common method of detection HPV, and as discussed, 
does not truly indicate HPV induced carcinogenesis. The actual proportion of HPV induced 
OSCCs still requires further clarification with exclusion of the base of tongue cancers and by 
utilising techniques that prove carcinogenesis, rather than simply presence of HPV in the 
tissue.  
 
The research to date in next generation sequencing (NGS) and oral cavity cancer has 
focussed on driver mutations and potential future druggable targets in these oral cavity 
cancers. The majority of NGS research in the oral cavity has largely relied upon DNA 
sequencing (both whole-genome and exome) 106-111. These studies were largely case series 
and a significant focus of this DNA sequencing work has reported changes in the NOTCH1 
gene 107, 110. These studies found that NOTCH1 had significant mutations in both cancerous 
and pre-cancerous lesions 107, 110. Other genes that were significantly affected in exome 
sequencing/DNA sequencing trials in all head and neck cancers include: TP53, CDKN2A, 
PIK3CA, HRAS, FBXW7, MLL2 and NSD1 112-114. In these studies, the focus was largely on 
identifying common mutations, with limited exploration of links of mutations with external 
variables. The most commonly explored variable with mutations in HNC and NGS was HPV, 
however this was complicated by the fact that most studies investigating this variable, pooled 
results from all HNCs, making extrapolation to understanding the aetiology of oral cavity 
cancers difficult. The reported literature investigating OSCC with NGS is rather limited due 
to the ongoing development and cost of this technology. Few hypotheses have been explored 
and ongoing research is still occurring.   
This literature review investigated the aetiology of OSCC, by exploring chronic dental 
trauma and  HPV. Additionally to a lesser extent the latest NGS work has been explored. The 
literature suggests that both chronic dental trauma and HPV may play a role in the aetiology 
of OSCC. There are a minimal number of published studies on the role of chronic dental 
trauma in carcinogenesis, largely due to difficulties in study design. However, several studies 
certainly suggest that chronic dental trauma does play a role, especially in the younger, non-
smoking population. The investigation of HPV as a carcinogen in the oral cavity has been 
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well studied over the past ten years, however large variability is seen in the literature. This 
may be due to differing techniques of detection, sample size, participant characteristics and 
the definition of oral cavity. Finally the emerging evidence from studies utilising next-
generation sequencing, have found several genes which may be responsible in the aetiology 
of OSCC. Overall this study will explore whether there is a link between all of these factors, 
and by designing a study utilising next-generation sequencing, this study may be able to 
definitively answer the following hypotheses.  	
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2.0	Hypotheses	
1. Oral cavity squamous cell carcinomas (OSCC) distinguish themselves from 
oropharyngeal squamous cell carcinoma in their aetiology and this is reflected in their 
genotype 
2. OSCC differ in the aetiology based upon tumour location within the oral cavity and 
this is reflected in their genotype  
3. The human papilloma virus (HPV) will not be a significant cause of OSCC, even in 
the non-smoking population 
4. There will be no significant differences in RNA expression between the samples 
based upon clinical demographic data 
5. There will be no significant differences in DNA exome mutations between the 
samples based upon clinical demographic data. 
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3.0	Methods	
 
This project was designed as a prospective observational study. The overall plan for this 
study was to collect fresh tissue samples from participants presenting to the Princess 
Alexandra Hospital (PAH) and Royal Brisbane and Women’s Hospital (RBWH) Head and 
Neck Cancer Clinics. This fresh tissue could then be used to address the hypotheses outlined 
above.  
 
A National Ethics Application Form (NEAF) was submitted to the Metro South Human 
Research Ethics Committee (HREC). Ethical approval for the study was granted on 
20/12/2012.  The NEAF application form can be found in Appendix A. The approval can be 
found in Appendix B. A Site Specific Application was applied for through the Princess 
Alexandra Hospital Governance Committee and the Royal Brisbane and Women’s Hospital 
Governance Committee. Governance approval was given on 20/9/2013.  
 
All potential participants were identified during either the PAH or RBWH clinic. Potential 
participants must have had a Squamous Cell Carincoma (SCC) localised to the oral cavity. 
The oral cavity for this study was defined as tumours arising from the anterior tongue, floor 
of mouth, alveolar ridge, buccal mucosa, hard palate and retromolar trigone. The soft palate 
and base of tongue lesions were considered to be part of the oropharynx, and not suitable for 
this study.  
 
Following identification, informed consent was obtained, either by the principal investigator 
or by a research nurse at one of the clinics. A copy of the consent form can by found in 
Appendix C. Following consent, demographic details were collected from the participant, 
either from directly questioning the participant or from the participant’s hospital chart. A 
copy of the clinical data collection form can be found in Appendix D. The demographic data 
collected is in Appendix E.  
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From the demographic data, three groups were identified based on smoking status: 
1. Life-long non-smokers – defined as participants who had smoked less than 1 pack 
year of cigarettes in their lifetime 
2. Ex-smokers – defined as participants who had ceased smoking at least 1 year prior to 
presentation with oral cavity cancer 
3. Current smokers – defined as participants who were smoking at the time of diagnosis, 
or who had quit smoking less than one year prior to being diagnosed with oral cavity 
cancer.  
This study involved the collection of fresh tissue samples for preparation of DNA and RNA 
sequencing to identify whether there are genetic or transcriptomal differences between the 
three groups that were being investigated.  
 
3.1	Sample	Collection	
Initially sample collection and storage utilised two different methods: 
1. Fresh biopsy of tissue was stored immediately on dry ice and transferred immediately 
to the laboratory, where it was transferred to a -80°c freezer 
2. Fresh biopsy of tissue was stored immediately in RNAlater at room temperature. It 
was then transferred to the laboratory and stored at 4°c overnight. The sample was 
then taken out of solution the next day and transferred to the -80°c freezer. 
Initially both techniques were used, as it was uncertain how each technique would result in 
the greater DNA and RNA stability for later extraction and sequencing. After the initial RNA 
extraction and analysis was performed (see method and results below), it was determined that 
the initial storage in RNAlater at room temperature and later transfer to -80°c was superior 
for RNA quality. Thus after the initial 3 samples were collected using both techniques, it was 
decided that all samples would be stored initially in RNAlater, rather than using dry ice. 
 
3.2	DNA	Extraction	and	Testing	
3.2.1	DNA	Extraction	
DNA extraction was performed using the Qiagen QIAMP DNA Mini Kit and directions were 
followed as per the tissue biopsy procedure: 
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1. The tissue was placed in a 1.5mL centrifuge tube with 180µL of Buffer ATL 
2. 20µL of Proteinase K was added to the sample, vortexed and incubated at 56°c 
overnight 
3. After vortexing the mixture, 200µL of Buffer AL was added to the sample, vortexed 
and then incubated at 70°c for 10 minutes 
4. After vortexing the mixture, 200µL of pure ethanol was added and vortexed 
5. The solution was then added to a QIAamp Mini Spin column and centrifuged at 
6000G for one minute, the filtrate was discarded 
6. 500µL of Buffer AW1 was added to the Spin column and centrifuged at 6000G for 
one minute, the filtrate was discarded 
7. 500µL of Buffer AW2 was added to the Spin column and centrifuged at 6000G for 
one minute, the filtrated was discarded  
8. 200µL of RNAse free water was added to the spin column and centrifuged at 6000G 
for one minute. This step was not repeated as was suggested in the kit handbook, as 
there was limited tissue available we did not want to reduce the DNA concentration 
9. All samples were tested on the Nandrop to asses for DNA quality (using the 
A260/280) and rough DNA concentration – Raw data is found in Appendix F. Figure 
1 shows the overall DNA yield from our samples, with Figure 2 demonstrating the 
quantity of DNA against it quality as measured on the nanodrop  
10. In order to allow for later DNA exome sequencing, RNA digestion was later 
performed on the tissue. 4µL of RNAse A was added to each sample and incubated at 
room temperature for two minutes. The samples were then incubated for five minutes 
at 37°c and then five minutes at 70°c. A repeat nanodrop analysis was performed 
following this digestion. The results are shown in Appendix G. Figure 4 showing the 
DNA yield against its quality as measured on the nanodrop. 
 
3.2.2	HC2	Testing	
The Qiagne digene HC2 High Risk HPV Test was performed on a limited number of the 
samples sent to the laboratory, the directions within this kit were followed: 
1. Samples obtained from the DNA extraction, negative controls and a high-risk control 
were pipetted into a 96 well plate and arranged as suggested in the test handbook  
 27 
2. 100µL of sample and 50µL of denaturation reagent were mixed into a 1.5mL 
centrifuge tube and incubated at 65°c for 45 minutes 
3. 75µL of each sample were pipetted into each well of the microplate wells along with 
the appropriate negative control and high-risk controls. This plate was incubated for 
10 minutes at room temperature 
4. 25µL of High-risk HPV probe mix was pipetted into each well. The plate was shaken 
on a rotary shaker at 1100rpm for three minutes 
5. The plate was incubated at 65°c for 60 minutes 
6. The contents of each well was transferred to the corresponding well on the capture 
microplate and was shaken at 1100rpm for 60 minutes at room temperature 
7. The plate was decanted and blotted 
8. 75µL of the detection reagent 1 was pipetted into each well. The plate was covered 
and incubated at room temperature for 30 minutes 
9. The plate was decanted and blotted, washed using the wash buffer, decanted and 
blotted 
10. 75µL of detection reagent 2 was added to each well of the microplate well 
11. The plate was then read on a luminometer 
12. The results are in Tables in Appendix H, and Figures 5 and 6. 
	
3.2.3	PCR	Testing	
Following HC2 testing, polymerase chain reaction was used to attempt to identify, using a 
highly sensitive process, any presence of HPV in the tissue. The primers utilised were the 
MY11 (GCACAGGGACATAATAATGG)/ MY09 (CGTCCAAGAGGATACTGATC), a 
well-known generic HPV primer 115 and  a HPV16Fwd 
(CCCAGCTGTAATCATGCATGGAGA)/ HPVRev 
(GTGTGCCCATTAACAGGTCTTCCA) specific primer was also utilised for this project116. 
HPV16 was selected as it is the most common HPV type to induce carcinogenesis in other 
regions of the head and neck, and additionally in the cervix 117. The final primer used was the 
beta-globin gene as a baseline control. The primer was Fwd 
(CAACTTCATCCACGTTCACC)/ Rev (GAAGAGCCAAGGACAGGTAC) 118.  To run the 
PCR the following procedure was followed: 
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1. Based on the results from the nanodrop analysis, appropriate dilutions were made for 
the extracted DNA to have an approximate concentration of 50ng in 3.75µL 
2. A mastermix was created using 95.625µL of Emerald mix (containing nucleotides, 
DNA polymerase, gel loading dye in an optimised buffer) 19.125µL of the forward 
primer and 19.125µL of the reverse primer. Three mastermixes were created with 
three different primers (as described above) – MY11/09, HPV16 specific primer and 
b-globin  (to be used a control)  
3. 3.75µL of the DNA solution and 8.75µL of the mastermix solution was added to each 
well of the PCR microwell plate 
4. A positive control was used (DNA from Caski cell line) and a negative control was 
used (water only)  
5. The plate was placed on the thermal cycler which ran at 95°c for one minute then 40 
cycles of: 95°c for 30 seconds, 57°c for one minute, 72°c for one minute. The 
program ended at 72°c for four minutes before returning to room temperature 
6. 12µL of each sample and 12µL of a DNA ladder was added onto a freshly prepared 
PCR agarose gel with GelRed DNA dye and ran at 100V for 45 minutes on an 
agarose gel electrophoresis machine 
7. Results were read under UV transilluminator. Results are shown Figure 7. 
 
All samples that had DNA extracted were sent for DNA exome sequencing to be performed 
by the Australian Genome Research Facility (AGRF). The samples underwent SureSelect 
Human All Exon library preparation, and were then sequenced on the Illumina HiSeq 2500.  
Following DNA exome sequencing, bioinformatics interpretation of the results was 
performed, this is described in results.  
3.3	RNA	Extraction	and	Testing	
3.3.1	RNA	Extraction	
RNA extraction was performed using the Qiagen RNeasy Mini Kit. As this project required 
extraction from solid tissue, a modified procedure was developed, in order to extract RNA 
with the maximum quality: 
1. Tissue biopsy was thawed on ice and added to 1mL of Trizol 
2. Tissue was homogenised on ice 
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3. Homogenised sample in Trizol incubated at room temperature for give minutes 
4. 0.2mL of chloroform was added to each sample and this was vigorously mixed 
5. The sample was incubated at room temperature for two-three minutes 
6. The sample was centrifuged at 12,000G for 15 minutes at 4°c 
7. 460µL of the upper aqueous layer was transferred into a 1.5mL centrifuge tube with 
460µL of freshly prepared 70% EtOH 
8. The solution was transferred to a RNeasy spin column in a collection tube 
9. The solution was centrifuged at 8000G for 15 seconds, the filtrate was discarded 
10. 700µL of RW1 buffer was added to the spin column. The column was centrifuged at 
8000G for 15 seconds, the filtrated was discarded 
11. An on column DNAse digest was performed using Qiagen RNase-free DNase kit. 
40µL of the DNase solution was added to each column and left to incubate for 15 
minutes 
12. 350µL of RW1 buffer was added to each column, centrifuged at 8000G for 15 
seconds and the filtrated was discarded 
13. 500µL of RPE buffer was added to each column, centrifuged at 8000G for 15 seconds 
and the filtrated was discarded. This step was repeated 
14. The spin column was then centrifuged at 8000G for 2 minutes to dry the column 
15. 50µL of RNase free water was added to each spin column 
16. The results were tested initially on the Nanodrop (after diluting the sample 1 parts 
RNA solution:4 parts water). These results are in Appendix I 
17. With the results of the nanodrop, appropriate dilutions were made to create RNA 
solutions approximately 200ng/µL in concentration. These were all tested on the 
bioanalyser for exact RNA concentrations and RNA integrity number (RIN) scores 
18. Results from bioanalyser testing are available in Appendix J. A plot of RNA yield 
against its quality is shown in Figure 7. 
 
From the extracted RNA, some samples were excluded from further library preparation, due 
to inadequate RNA quality. If RNA quality had a RIN score less than 1.4, these samples were 
excluded from further testing. The RIN score is a measure of RNA quality and rates RNA 
quality from 1-10. The RIN score has been developed and included in the Agilent 
Bioanalyser Software manufactured by Agilent 119 
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3.3.2	RNA	Library	Preparation	and	Sequencing	
Adequate RNA samples proceeded to cDNA library preparation. Library preparation utilised 
the Illumina Tru Seq v2 library preparation protocol 120. As per the protocol, bioanalyser 
testing occurred of the samples prior to sequencing, these results are in Appendix K.  
 
RNA sequencing was completed by the University of Queensland Centre of Clinical 
Genomics. Samples were sequenced on the Illumina HiSeq 4000 with a maximum of 12 
libraries per sequencing lane, sequenced files were outputted in the format of a FastQ file. 
Bioinformatics was then utilised to analyse the data. Quality control of the data was initially 
performed by using the fastQC tool 121. The raw reads were then aligned to the human 
genome utilising the the STAR tool 122.  
 
The sequenced data was initially mapped to the human genome (GENCODE v23)123 along 
with the HPV genome, and specifically HPV16 (HPV16, NC_001526)124, to identify whether 
HPV replication was occurring within the tissue. This data was correlated with the 
participants smoking status and other demographic details (See table 3). E6 and E7 
expression was also explored and correlated this with the HPV status (Figures 9 & 10).  
 
Following initial testing, advanced testing using the Weighted Gene Co-Expression Network 
Analysis (WGCNA) was performed, this is described in further detail below.   
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4.0	Results	and	Discussion	
 
This study examined possible aetiologies of oral cavity squamous cell cancer (OSCC) in a 
non-smoking population. There are several hypotheses about the aetiology of OSCC, and 
utilising a variety of techniques, the hypotheses described in section 2.0 were tested.  
To test the hypothesis that HPV infection might contribute to the aetiology of a subset of 
OSCCs, OSCC samples were tested for HPV DNA and RNA. To ensure that DNA yield and 
quality was adequate prior to further experimentation, Nanodrop analysis assessed the quality 
and quantity of DNA extracted. As shown in Figures 1 , 2 and 3,  sufficient quality DNA was 
extractable from the tumour samples to proceed with further testing. The OSCC DNA was 
used in testing using the HC2 test (Section 4.1), PCR (Section 4.2)  and finally DNA exome 
sequencing (Section 4.4).  
  
 
Figure 1: The biopsies from OSCCs reveal adequate DNA yields from most samples. 
To assess adequacy of DNA extraction, DNA quantity was assessed by Nanodrop analysis 
and was regarded sufficient if the total quantity was greater than 1mg.  
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Figure 2: The DNA extracted from OSCC samples shows no correlation between DNA yield 
and DNA quality. 
DNA quality was assessed on Nanodrop by the A260/280 ratio, with an A260/280 ratio >1.8 
considered to be adequate DNA quality. 
  
Figure 3: Following RNAse digestion, the OSCC DNA samples still show adequate DNA 
quality and no correlation was observed between final DNA yield and DNA quality 
As shown in Figure 2, DNA quality was assessed using the Nanodrop analysis using the 
A260/280 ratio. DNA quality was considered sufficient if the A260/280 ratio was >1.8.  
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4.1	HC2	Testing	
 
The initial test for HPV presence in OSCC DNA samples involved using the Qiagen digene 
HC2 High Risk HPV test kit. This was for a rapid assessment of HPV status, using clinically 
utilised methods. The Qiagen digene HC2 test kit was initially designed to test for the 
presence of high risk HPV DNA in cervical samples from colposcopy. The HC2 test kit 
works by first mixing the OSCC sample DNA solution with a HPV RNA probe mix. If there 
is the presence of the high-risk HPV DNA (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 and 68) within the solution it binds with the HPV RNA probe. The mix is then added 
to the microplate. If there is binding between the DNA and RNA probe, this hybrid is caught 
on the surface of a microplate which has been coated with antibodies which specifically bind 
with RNA/DNA hybrids. In a series of reactions, alkaline phosphatase is bound to the 
RNA/DNA hybrid and in the process of the hybrid being cleaved, light is emitted which is 
measured on a luminometer. Using a series of internal controls, each individual sample’s 
luminescence is compared against these internal controls to determine whether the sample 
could be considered high risk HPV positive or negative. Any sample with a ratio to the 
internal controls greater than one, is considered positive for the presence of high risk HPV 
DNA. Conversely any sample with a ratio less than one, is considered high risk HPV 
negative 125. As shown in Figures 4 and 5, none of the 14 OSCC samples were observed to 
have a ratio greater than one, indicating a lack of high risk HPV within the tissue. The Qiagen 
HC2 test kit requires approximately 5000 copies of HPV DNA to test positive, thus the 
limitation of this technique is with OSCC samples with low HPV counts. Therefore, PCR 
was utilised as a more sensitive measure of HPV presence.  
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Figures 4a and 4b: There was no evidence of high risk HPV DNA being present in the 
fourteen OSCC samples that were run on the HC2 test kit 
DNA extracted from 14 OSCCs were run through the Qiagen HC2 test kit. Luminometer 
readings from each sample are compared to luminometer readings from an internal control. 
Any OSCC sample with a. luminometer reading greater than the internal controls (ratio 
greater than 1), is deemed positive. Both runs (A & B) shown are considered valid as the high 
risk HPV control (QC-HR) is considered positive and low risk HPV control (QC-LR) is 
considered negative. 
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Figure 5: DNA extracted from OSCC samples do not reveal presence of HPV16 DNA, however one 
sample tests positive utilising a generic HPV primer 
DNA extracted from 14 OSCCs were subjected to 30 rounds of PCR amplification using a HPV specific 
primer (upper panel), generic HPV primers (MY11/09) (middle panel) and beta-globin primers as a 
positive control (bottom panel). The agarose gel was stained with GelRed dye. Negative control was 
water. Positive control was extracted DNA from the Caski cell line. Sample 2014037004 tested positive 
only with the generic HPV primer pair. 
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4.2	PCR	Testing	
 
To establish whether HPV DNA was present in the oral cancer samples, DNA extracted from 
14 oral cancers were subjected to 30 rounds of PCR amplification using the primers, detailed 
in section 3.2.3, specific for the E6/E7 genes of HPV16 and additionally using a generic 
primer pair detecting a relatively conserved sequence of the HPV L1 gene from the majority 
of alpha- papillomaviruses. As shown in Figure 5, only one of the 14 samples (2014037004)  
tested positive in this experiment with the generic primer pair, and none with the HPV 
specific primer pair.  
 
This PCR test is highly sensitive for  detection of  HPV DNA. The literature shows that 
HPV16 specific primer can  detect as few as five copies of the E6 gene of HPV16 per sample 
following 35 rounds of amplification 116. However, this study only did a total of 30 cycles of 
PCR and there is limited evidence on the use of only 30 cycles with the HPV16 specific 
primer. However, the Caski cell line is known to contain 600 copies of the HPV16 per 
genome and the Caski control tested positive with 30 cycles of the PCR with the HPV16 
specific primer 126. Thus, whilst there was currently no sensitivity data for this HPV16 
specific primer when using 30 cycles of PCR, as no OSCC sample tested positive, these 
samples were either HPV negative or contained less than 600 copies per genome of HPV16. 
This was significantly more sensitive than the HC2 testing. However, the fact that this study 
only ran the PCR with 30 cycles, rather than 35-40 where there is more evidence, is an error 
of experimental design. If this study was to be repeated, a minimum of 35 cycles of PCR 
would be performed. The MY11/09 primer has been demonstrated to be a sensitive test for 
HPV DNA with 30 cycles of PCR, being able to detect as little as 0.04pg of HPV DNA 127. 
One microgram of an 8000bp length is equivalent to 1.9 x 10-13 moles of DNA. When 
multiplied by Avogadros number, the number of molecules of HPV DNA in 1 microgram 
would be 1.14x 1011 molecules. Dividing by 2.5 x 107 to calculate the number of molecules in 
0.04pg of HPV DNA, the final number of HPV molecules in 0.04pg of HPV is approximately 
4500. In total there was 50ng of DNA per sample, which is approximately equivalent to the 
weight of 10,000 cells. Even if the tumour sample contained less than 50% tumour cells, this 
assay should be sensitive enough to detect the presence of HPV, assuming one copy of HPV 
DNA per cell. Overall MY11/09 is a sensitive marker of HPV presence in the tissue. Thus 
both of these primers represent a more sensitive marker of HPV DNA presence in the tissue 
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compared with the HC2 testing. Even with these more sensitive detection systems, HPV 
wasn’t detected in the OSCC tissue samples. 
 
As discussed in section 1.0, PCR has been utilised as a method of detection of HPV in OSCC 
in many studies. The reported rate of HPV DNA presence is extremely variable from 0-100% 
in the literature. As discussed in section 1.0, the reason for such variability is multifactorial. 
However, the limitation of utilising HC2 and PCR is that both techniques are only able to 
detect the presence of HPV in the tissue. If HPV had induced carcinogenesis, but was then 
cleared from the tissue, both PCR and HC2 testing could be negative. 
 
In order to further clarify  the potential of HPV induced carcinogenesis within these OSCC 
samples, RNA sequencing was utilised. 
 
4.3	RNA	Sequencing	
 
4.3.1	HPV	and	E6/E7	mRNA	Expression	
To ensure that RNA yield and quality was adequate prior to further experimentation, 
Nanodrop analysis assessed the quality and quantity of RNA extracted. As shown in Figure 6, 
it was observed that there was sufficient RNA quantity and quality to proceed with further 
testing. To test the hypothesis that HPV was responsible for inducing carcinogensis within 
some OSCC samples, the first testing, utilising RNAseq, was to identify HPV mRNA in the 
sequenced samples. Following alignment of the RNAseq data to the Gencode v23 with HPV 
virus sequences added, HPV RNA was present in 2/40 samples (5%) (See Table 3). The HPV 
RNA type present was HPV16. Of note, both these samples came from participants who were 
in the “current smokers”  group. Additionally, neither of these two positive results came from 
the OSCC sample that was positive with the PCR with MY11/09 primer.  
To test that hypothesis that HPV might be promoting carcinogenesis in these samples,  raw 
read counts of E6 and E7 virus oncoprotein mRNA were determined for all samples. As 
shown in Figures 7a and 7b, the two samples with HPV16 RNA showed high E6 and E7 
mRNA read counts, consistent with HPV induced carcinogenesis and only these samples had 
significant reads corresponding to the E6 and E7 gene sequences. 
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E6 and E7 are two oncoproteins which are produced by the HPV virus. HPV DNA is 
episomal in vegetative viral reproduction, which is assisted by the virally encoded E6 and E7 
proteins.  However, in HPV associated cancers, there is integration of the HPV virus into the 
host genome and, commonly, only the  E6 and E7 proteins are produced. Both E6 and E7 
affect cell-dependent kinases 105. E6 is responsible for p53 degradation and its expression 
enables progression of the cell cycle through the G2/M checkpoint and cell division even in 
the presence of DNA damage. Retinoblastoma protein (pRb) normally binds and inhibits the 
action of E2F which enables progression through the cell cycle at the G1 checkpoint. E7 acts 
as an oncoprotein by binding to and inhibiting the action of pRb, allowing E2F to drive cell 
cycle progression through the G1 checkpoint. Overall HPV, through the actions of E6 and E7 
oncogenes, can promote cell proliferation, even in the face of DNA damage and hence 
enhances the risk of cancer development. E6 and E7 mRNA expression in a tumour sample 
suggests strongly that HPV is contributing to development of the cancer. Therefore, it can be 
concluded that, for the two participants in the current study with detectable HPV16 E7 and 
E7 mRNA in their samples, despite their significant tobacco exposure, their OSCC is at least 
in part due to the action of the HPV. However, only in the minority of subjects in the current 
study were there HPV transcripts to suggest that HPV had been a driver of OSCC 
development: in the vast majority of participants there was no evidence that HPV was  
responsible for oncogenesis. 
 
These results add to the body of evidence to suggest that in the oral cavity, HPV does not 
play a significant role in carcinogenesis. This is in stark contrast to OPSCC, where non-
smoking patients typically have disease which is the result of HPV infection 102, 103. This 
work was reflected in the recently published TCGA data with RNAseq, which showed only 
6% of non-oropharyngeal head and neck cancer had high HPV reads and increased E6/E7 
expression 128. This is contrast to oropharyngeal SCC, which typically has a high proportion 
of disease which is due to HPV. This suggests that the oral cavity and the oropharynx are 
anatomically and pathologically two very distinct sites, which should not be grouped together 
when discussing carcinogenesis.    
 39 
Table 3 – RNAseq – HPV status and Smoking Status 
Identification	
Number 
Smoking Status HPV Presence 
(Type) 
P16 staining P16 Expression 
2013155003 Ex-Smoker Negative Not	done Low 
2013162003 Current	Smoker Negative Not	done High 
2103218002 Ex-Smoker Negative Not	done Low 
2013262001 Non-Smoker Negative Not	done Low 
2013255013 Ex-Smoker Negative Not	done High 
2013232002 Current	Smoker Negative Not	done Low 
2013246002 Current	Smoker Negative Not	done Low 
2013274001 Current	Smoker Negative Not	done Low 
2013315002 Current	Smoker Negative Not	done Low 
2013302002 Non-Smoker Negative Not	done Low 
2013350001 Ex-Smoker Negative P16	Negative Low 
2013350002 Non-Smoker Negative P16	Positive Low 
2014079003 Non-Smoker Negative P16	Positive Low 
2014079005 Current	Smoker Negative Not	done High 
2014086001 Current	Smoker Negative Not	done Low 
2014142002 Ex-Smoker Negative P16	Negative Low 
2014142004 Non-Smoker Negative Not	done Low 
2014150001 Current	Smoker Negative P16	Negative Low 
2014156001 Current	Smoker Negative Not	done Low 
2014156003 Current	Smoker Negative Not	done Low 
2014183001 Ex-Smoker Negative Not	done Low 
2014192001 Current	Smoker Negative P16	Positive Low 
2014199003 Ex-Smoker Negative Not	done Low 
2014206001 Current	Smoker Negative P16	Negative Low 
2014230001 Current	Smoker 
Positive 
(HPV16) Not	done 
High 
2014262001 Current	Smoker Negative Not	done Low 
2014309001 Current	Smoker Negative Not	done Low 
2014338002B Ex-Smoker Negative Not	done Low 
2014342001 Current	Smoker Negative P16	Positive Low 
2014344001 Ex-Smoker Negative Not	done Low 
2014345001 Current	Smoker Negative Not	done High 
2015012001 Current	Smoker Negative Not	done Low 
2015145001 Current	Smoker Negative Not	done Low 
2015194001 Current	Smoker 
Positive 
(HPV16) Not	done 
High 
2015197001 Ex-Smoker Negative P16	Negative High 
2015201001 Ex-Smoker Negative Not	done Low 
2015204001 Ex-Smoker Negative Not	done Low 
2015253001 Ex-Smoker Negative P16	Negative Low 
 
  
 40 
 
Figure 6: The RNA extracted from OSCC samples shows no correlation between RNA yield 
and RNA quality 
 RNA quality was assessed on Nanodrop by A260/280 readings. R2 value <0.1 indicating no 
correlation between RNA concentration and A260/280.  
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Figures 7a & b: Two OSCC samples showed high E6 and E7 mRNA read counts 
Following mapping of the RNAseq data to the HPV16 genome, mRNA levels of E6 (Figure 
7a) and E7 (Figure 7b) were determined from the raw read counts. * Indicates positive for 
HPV mRNA presence. Note that the only samples with high E6/E7 raw read counts are the 
additionally the samples that are positive for HPV mRNA.  
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4.3.2	CDKN2A	(p16)	Expression	
This study then investigated the utility of p16 staining in the oral cavity. p16 
immunohistochemical staining has a well-documented association with HPV positive OPSCC 
129. Consequently, p16 staining is relied upon to determine the appropriate treatment modality 
in the oropharynx, as HPV positive tumours are more likely to respond to 
chemoradiotherapy. Thus it is of interest to determine whether p16 could be reliably utilised 
as a marker for HPV positive disease in the oral cavity. To test whether the CDKN2A gene 
product, otherwise known as p16, is a reliable marker for HPV induced disease in OSCC 
samples, raw read counts for CDKN2A mRNA were determined for each sample (Figure 8). 
This information was then compared with the clinically collected details and for HPV mRNA 
data ( Table 3). 
 
Figure 8: CDKN2A mRNA expression is not a specific marker for HPV positive OSCC 
 
Normalised counts for CDKN2A mRNA were plotted for all OSCC samples and HPV 
positive samples are shown in blue.  
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As shown in Table 3, p16 staining in the clinical setting was undertaken in around 50% of 
cases in the current study. In the three samples that were classified as p16 positive by a 
pathologist, none were considered to have high expression of p16 utilising RNAseq. 
Likewise, none of the tissue with high p16 expression showed positive p16 on 
immunohistochemical staining. Of note, both samples that were HPV positive did have high 
p16 mRNA expression in the tissue, suggesting that CDKN2A (P16) mRNA expression might 
indicate HPV related disease. However, there were other samples which were HPV negative 
that had equally high P16 expression. Thus whilst detection of p16 expression by mRNA 
analysis could be considered a sensitive test for HPV, it is not specific. Therefore, in the oral 
cavity, p16 immunohistochemistry and mRNA expression should not be relied upon to 
determine HPV status and thus has limited utility in clinical practice. This lack of association 
between HPV and p16 in the oral cavity has been discussed in other published literature 74. 
 
4.3.3	Principal	Component	Analyses		
To test whether there were  significant differences in mRNA expression between the OSCC 
samples in the current study that related to clinical demographic data, a principal component 
analysis (PCA) was first utilised. PCA can subset RNAseq data, by looking for the 
components with the most variance in the data. The OSCC samples are plotted on a scatter 
plot with the X and Y axes representing the two highest principal components, the variables 
which explain the most variance between the samples. Clustering of the samples can then be 
analysed; in particular, it can be explored whether clustering of plots on the scatter plot can 
be explained by chosen variables, such as the demographic details collected for the current 
study. For this study, the variables of interest to the original hypotheses were: smoking status, 
tumour stage and tumour location. 
 
To test the hypothesis that OSCC samples would be grouped by smoking status, the PCA was 
utilised. As shown in Figure 9a, this study observed no obvious clustering separating the 
three smoking status groups. This is a significant negative finding, as this was a key 
hypothesis to be explored in this study. As previously outlined, this study was attempting to 
utilise next-generation sequencing technologies to attempt to explain the aetiology of OSCC 
in the non-smoking population. However, as mentioned, the PCA only takes into account the 
two principal components which explain the majority of the variance in mRNA expression 
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between the samples. If there are more subtle differences in the mRNA transcriptome, this 
would not be shown in the PCA. 
 
To test whether tumours showed different transcriptomes according to clinical staging, PCA 
was again utilised. As shown in Figure 9b, it was shown that there was no clustering on the 
PCA based upon tumour stage at the time of diagnosis. This indicates that tumours which 
potentially were more aggressive (advanced stage at diagnosis), show a similar mRNA 
transcriptome to less aggressive tumours. However, this requires further data collection, as 
tumour stage at the time of diagnosis as a surrogate for disease aggressiveness is confounded 
by individual patient factors, such as late presentation to hospital. 
 
As discussed in section 1.0, previous studies have implicated chronic dental trauma as a 
cause for oral cavity cancer, especially in the non-smoking population. A previous study, 
found that OSCCs in the non-smoking population, were more likely to occur at sites of 
chronic dental trauma, namely the lateral tongue and buccal mucosa6. However, in the 
smoking population, the tumour location distribution within the oral cavity was more evenly 
spread throughout the entire oral cavity. Thus it was proposed that the aetiology of some oral 
cavity cancers may be secondary to chronic dental trauma. To explore whether tumour 
location would influence the mRNA transcriptome, the PCA was again utilised.  As shown in 
Figure 9c, there is no clustering based upon tumour location. Furthermore, as seen in figure 
14, there is again no clustering  when using the binary value of areas of chronic dental trauma 
(tongue and buccal mucosa) vs other locations within the oral cavity. Thus, the RNAseq data 
does not confirm that there is a differing underlying transcriptomal differences between 
tumours arising in areas of chronic dental trauma versus areas not associated with chronic 
dental trauma. Therefore, the underlying aetiology between tumours arising in areas of 
chronic trauma potentially is the same as those tumours arising elsewhere within the oral 
cavity. 
To further test whether any clustering was obvious based upon the demographic details 
collected, a gene dendrogram was constructed with OSCC being clustered based upon PCA 
similarity. As shown in Figure 10, there was no clustering of samples based upon the 
demographics collected including: age, gender, TNM staging, smoking status, alcohol 
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consumption and p16 immunohistochemical staining. This indicates that either there was 
truly no demographic detail which explained the major variances in the RNA transcriptome, 
or that a different demographic detail that was not collected could have explained the major 
variances, or there was insufficient power to detect a difference. This may have been the 
situation with the use of the PCA in this cohort. As only 45 OSCC samples were sequenced, 
this may have limited the power to detect significant differences in the transcriptome. 
 
Thus as HPV was not a significant cause of OSCC in this study and as the transcriptome of 
OSCC samples was not subdivisible according to clinical features of the tumours by PCA, 
further analysis of the RNAseq data was performed, using a weighted gene co-expression 
network analysis (WGCNA).   
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Figures 9a-d: Major variances in RNAseq data not explained by smoking status, tumour stage 
or tumour location 
 
PCA were performed on the RNAseq data from all OSCC samples according to the status for 
smoking status (9a), tumour stage in TNM staging (9b), and tumour location (9c shows all 
locations, 9d shows areas of chronic dental trauma – tongue and buccal areas – compared 
with all other areas of the oral cavity). Circles represent 80% confidence intervals. 
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Figure 10: Gene Dendrogram from RNAseq data reveals no clustering of participants based 
upon demographics collected 
 
RNAseq data were clustered by similarity according to RNAseq Principal Component 
Analysis.  
	
4.3.4	WGCNA	Analysis		
In order to further analyse for trends related to the demographics collected, the RNAseq data 
was explored utilising the WGCNA package. This has the advantage of exploring 
components of the data which may not be reflected in the principal component analysis. In 
order to account for genes of different sizes, normalisation of the data was performed with 
the limma-voom package 130. Voom-transformed counts of the normalised expression data 
were used for input in the WGCNA package 42. WGCNA has the advantage in this study of 
being able to compare genetic traits across multiple hypotheses simultaneously. This was 
undertaken to discover possible differential gene expression changes between our three 
smoking groups, along with other demographic variables including p16 staining, alcohol 
consumption and tumour staging. Additionally, this package would allow, utilising 
hierarchical clustering, identification of groups/modules of genes with a dissimilarity 
measure of the topology overlap matrix (TOM). Using Pearson correlations, the concordance 
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between expression profiles of the different demographics was determined and thus used to 
define the dissimilarity between genes. Using this dissimilarity between genes, biological 
modules were created. These defined modules are demonstrated in Figure 11. Appendix L 
lists the eigengene modules and associated gene ontology terms. Modules with similar genes 
were created utilising the WGCNA package, which allowed exploration of common 
pathways that were up- or down-regulated in the groups determined by the demographics 
collected. A graphic representation of the eigengene modules against the collected 
demographics is shown in Figure 12.  
Figure 11: WGCNA determined clustering gene dendrogram and module definition with 
associated module colours 
For methodology see method section 4.3.4. The WCGNA package defines modules, which 
are then used in Figure 12 to link the data with demographics collected. 
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Figure 12: Demographics plotted against the defined eigengene modules from WCGNA 
analysis demonstrating multiple significant relationships between modules and demographic 
data  
 
The correlation value (top value) and p value (bottom value) for each module and 
demographic trait are listed. Red samples are positively correlated; blue samples are 
negatively correlated, with more strongly positively or negatively correlated modules having 
a more positive or negative number respectively. 
 
As shown in figure 12, advanced disease (higher TNM stage) was correlated with up-
regulation of the pink eigengene module, which is predominantly related to immunological 
processes. This is biologically plausible, that higher grade tumours had an overexpression of 
immune system pathways as an attempted defence mechanism against further tumour 
progression. Advancing TNM stage and immune system progression has been previously 
demonstrated in multiple other cancer types, including colorectal and hepatocellular 
carcinoma131, 132. However, there is also a significant negative correlation between advanced 
stage and the greenyellow module, which is closely related to gene expression related to 
antigen processing. This may represent one of the so-called ‘escape mechanisms’ of the 
tumour against the immune system131, however is somewhat inconsistent with the up-
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regulation of the immunological system pathways shown in the pink module. Finally, when 
investigating advancing TNM staging, the red eigengene module was down-regulated, this 
module contains multiple gene ontology terms which are related to the oxidative 
phosphorylation pathway. This again is biologically plausible, as tumours known to down-
regulate oxidative phosphorylation pathways in preference for anaerobic glycolysis, an effect 
known as the Warburg effect 133. Thus with a higher tumour burden, these pathways become 
further down-regulated, explaining this effect seen in our samples. Overall, the effects shown 
with advancing TNM staging are biologically plausible and may represent useful adjuncts in 
targeting advanced disease, or with providing patients with better prognostic information.  
 
The differences between smoking status  groups were of interest to this study. The aetiology 
of OSCC in the non-smoking population has been unclear from previous studies and it was 
hoped that this study would elucidate a transcriptome element to the disease in this 
population. The eigengene module brown was positively correlated to those participants who 
had ever smoked (current and ex-smokers combined), compared with the non-smoking 
population. The brown module was associated with increased mTOR signalling, increased 
EGFR pathway and toll-like receptor 4 (TLR-4) signalling. Some of these associations have 
been previously explored in HNCs and other cancers. The mTOR pathway has been linked to 
multiple cancers, most of which are smoking related: laryngeal SCC, small cell lung 
carcinoma and transitional cell bladder carcinoma 134-138. Work performed in lung carcinoma 
has shown the ability of extracts from cigarette smoke to drive activators of the mTOR 
pathway 137. Additionally, in a study on laryngeal SCC, a cancer which is strongly correlated 
with tobacco exposure, mTOR and EGFR pathways were highly overexpressed. However, no 
study was identified which found links between the mTOR pathway and compared the effects 
between smoking and non-smoking groups, making a comparison with this study difficult. Of 
interest, mTOR signalling has been previously linked to disease prognosis, with poor 
prognosis linked with high mTOR signalling 135. Whilst disease survival was not collected as 
a part of our study, there was no correlation between TNM stage (a somewhat poor surrogate 
for prognosis) and the eigengene module brown.  
Also upregulated as part of the brown module, were pathways associated with epidermal 
growth factor receptor signalling. Whilst previously not extensively studied in OSCC or 
HNC, the link between smoking and EGFR signalling is well established in lung 
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adenocarcinoma139-144. This is of particular interest in lung adenocarcinoma, as therapeutics 
targeting aberrations in this pathway, specifically tyrosine kinase inhibitors, are of therapeutic 
use143, 145. Furthermore, continued smoking post diagnosis with lung adenocarcinoma 
sensitive to tyrosine kinase inhibitors also promotes tumour resistance to these inhibitors by 
inducing further mutations in the EGFR pathway143. Use of tyrosine kinase inhibitors in 
OSCC patients with EGFR signalling pathway alterations, may prove a new therapeutic 
opportunity to exploit with the ongoing research and application of NGS. Further research is 
required into the utility of tyrosine kinase inhibitors in the oral cavity cancer population, 
especially the smoking or ex-smoking population. Overall, the up-regulation in mTOR and 
EGFR pathways exclusively in the smoking population may indicate that there are 
genetically different drivers in the smoking population, compared with non-smokers. 
However, studies that are more highly powered are required to investigate this further. 
 
Finally, to test the hypotheses that: 
1. Oral cavity squamous cell carcinomas (OSCC) distinguish themselves from 
oropharyngeal squamous cell carcinoma in their aetiology, and this is reflected in 
their genotype and 
2. OSCC differ in the aetiology based upon tumour location within the oral cavity, and 
this is reflected in their genotype, 
the WGCNA package was again used, along with external data from The Cancer Genome 
Atlas (TCGA). Firstly, TCGA data was downloaded from https://tcga-data.nci.nih.gov on the 
7/4/2016. Demographic data was also downloaded from TCGA to identify the tumour 
location from sequencing data from the head and neck cohort. Firstly, the data was explored  
to identify any concordance between the sequenced oral cavity data from this study and the 
TCGA data on oropharyngeal tumours. As shown in Figure 13, there was no preservation of 
eigengene modules when overlaying the WCGNA determined eigengene modules from this 
study’s oral cavity data and the TCGA OPSCC data. Thus indicating that a difference in the 
RNA transcriptome between OSCC and OPSCC.   
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Figure 13: No WCGNA module preservation between this study’s OSCC data and TCGA 
Oropharyngeal SCC data, indicating that underlying transcriptome is dissimilar between 
these datasets 
Utilising the WCGNA package, modules were defined for both the data from this study (See 
figure 11) and for TCGA data for oropharyngeal SCCs (OPSCC) and then overlayed. 
 
In order to validate these differences, the same process was repeated to overlay the defined 
eigengene modules from this study with TCGA oral cavity SCC created modules. As shown 
in Figures 14a and 14b there was again no module preservation when these two data sets 
were overlayed. Thus suggesting that the TCGA and this study’s OSCC cohort did not share 
the same RNA transcriptome. 
 
Thus, whilst initially it was concluded that the pattern in RNA transcription differed between 
OSCC and oropharyngeal SCC, Figures 14a and 14b show that this study’s data and the 
TCGA OSCC also do not show module preservation. Thus is must be concluded that this 
study’s data set shows a different transcriptome pattern from both the TCGA OSCC and 
OPSCC data. The reason for these differences is unknown, however may be due to low 
power in this study with a small sample size in this study’s cohort compared with the large 
data set from TCGA. Additionally, with most of the data coming from the USA in the TCGA, 
other local environmental factors may influence the HNC transcriptome patterns seen in the 
TCGA data compared with the data from this study.  
 
 53 
  
 
Figure 14a & 14b: No module preservation is observed between TCGA OSCC RNAseq data 
and this study’s OSCC RNAseq data 
14a shows module construction using WGCNA package for the TCGA OSCC samples. 14b 
shows 14a overlaying the RNAseq OSCC data from this study.  
	
4.4	DNA	Exome	Sequencing		
 
The final work within this study utilised DNA exome sequencing data to identify whether 
underlying mutations could explain the differences between the participants. The analysis 
was completed using the Broad Institutes GATK Best Practice Workflow for Somatic SNPs 
(See Figure 15) 146.  
 
As no matched normal tissue was collected for this study, data from participants of the 1000 
genomes project147 was included as the panel of normal to exclude common germline genetic 
variations. Specifically, data from the 1000 genomes project phase 3 release was used: 2504 
participants across 26 populations, sequenced on various Illumina platforms (HiSeq2000 and 
newer platforms). Furthermore, the data was filtered with dbSNP v138 database 148 (NCBI’s 
catalogue of common germline variants). Known somatic mutations in the Catalogue of 
Somatic Mutations in Cancer (COSMIC) v77 database149 was used to exclude rare allele 
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frequencies and low confidence calls from the analysis, as well as rescue common, high-
confidence somatic calls filtered from dbSNP and a panel of normal filters. This resulted in 
the generation of approximately 80,000 variants across 45 samples - around 70,000 Single 
Nucleotide Polymorphisms (SNPs) and around 10,000 insertions/deletions (indels). The total 
resulting number of SNPs was roughly 1,500 per sample. 
Figure 15: Best Practice Protocol for somatic mutation discovery in exome sequencing 
 
To help identify which mutations could be relevant to our understanding to the differences 
between our groups, 31 commonly mutated genes from HNCs were identified from the 
literature.  
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These genes were: 
• TP53 
• NSD1 
• HUWE1 
• DYSF 
• CDKN2A 
• PIK3CA 
• RB1 
• KMT2D 
• KDM6A 
• HRAS 
• CREBBP 
• ZNF750 
• THSD7A 
• NOTCH1 
• EPHA2 
• EP300 
• CASP8 
• ASXL1 
• PTPN14 
• FAT1 
• AJUBA 
• TFGBR2 
• IRS4 
• FBXW7 
• PTEN 
• NLRP8 
• KEAP1 
• PIK3R1 
• NFE2L2 
• HLA-B 
• CUL3 112, 150 
 
Following this protocol, this study was able to identify the single nucleotide polymorphisms 
(SNPs) seen within the DNA exome sequencing data. The SNPs were then imported into the 
GenVisR package. By utilising the GenVisR R package, easy visualisation of the number and 
type of mutation present within the samples was possible. The output from this package is 
shown in Figures 16-19.  
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Figure 16: There was no significant differences in numbers or type of mutations seen in 
OSCC DNA exome sequencing data 
Exome sequencing was performed on 45 OSCC samples and mutations defined using the 
algorithm described in Figure 15 and in the results section 4.4.  
 
Figure 17: The most common DNA mutation seen were seen in TP53, with NSD1 having a 
high number of synonymous mutations 
 
Comparisons were made based on exome sequencing data as displayed 16. Red bars correlate 
with synonymous mutations, whereas blue bars correspond with non-synonymous mutations. 
For additional clarification see Figure 18.  
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Figure 18: Gene mutation plot showing the most commonly mutated genes 
 
The genes listed along the Y axis, are listed in order of mutation prevalence amongst this 
cohort. The legend on the right side indicates the type of mutation present in each gene for 
that participant. The list of mutation types is ordered in severity as per the GenVisR package, 
with non-sense mutations being considered the most severe and silent mutations the least 
severe mutation.  
 
Figure 19: No clustering demonstrated in demographics based upon DNA exome mutations  
Mutations defined from OSCC exome sequencing data were correlated with demographic 
data.  
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To ensure that there were no significant outliers in the numbers or type of mutations, the 
numbers of detected SNPs and type of mutation was plotted. As shown in Figure 16, there 
was no significant outliers either in the number or type of mutations seen within this data. To 
assess the most frequently mutated genes within this group of OSCC samples, the numbers of 
gene mutations were plotted (Figure 17) along with the type of mutation (Figure 18). 
 
As shown in Figure 17 and 18, the most common mutation seen in this study was in TP53. 
Furthermore, Figure 18 demonstrates that the mutations in TP53 were significant, with all 
mutations being more severe than silent, intergenic region, intro or 3’UTR mutations. 
Significant mutations in TP53 was not unexpected, as TP53 is a key tumour suppressor gene, 
known to be significantly affected in many squamous cell carcinomas. Wild-type p53 acts as 
a tumour suppressor gene, preventing rapid cell turnover. TP53 protein acts to cause 
quiescence, senescence or apoptosis in cells, preventing propagation of harmful DNA 
changes151. Heterozygous or even homozygous mutations in the p53 gene lead to decreased 
or lack of production of the p53 protein, leading to increased cell cycle propagation. Many 
cancers in the human body show mutations in p53, including HNC and OSCC. A review into 
HNC found that 32% showed p53 mutations. Other research has found p53 mutations in 
HNC in over 42% of tumours 152. 
 
Of note, these other studies found p53 mutations tended to occur more commonly in tumours 
from smoking participants152. To assess whether smoking status, or other demographic 
factors could explain which OSCC samples exhibited particular mutations, the samples were 
clustered according to their mutations and this information was correlated with the 
demographics collected. As shown in Figure 19, no clustering was observed of the 
demographic data when the samples were clustered as per the exome sequencing mutations. 
However this is limited by the small sample size, the relatively small number of mutations 
and that the majority of the clustering of samples was based on TP53 mutations. The initial 
work from TCGA has found in all HNCs, p53 mutations additionally occurred significantly 
more commonly in HPV negative tumours (86%) compared with HPV positive tumours 
(2.4%) 128. It is difficult to compare this result with the results from this study. Whilst the rate 
of TP53 mutations in HPV positive tumours was 0%, with a sample size of 2 for HPV 
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positive tumours, there is insufficient power to correlate this result with the results from 
TCGA. TCGA also reported on a correlation between p53 mutations and survival 128. 
Survival data wasn’t collected as a part of this study, however if we use the crude marker of 
tumour stage as a surrogate for survival, our data does not correlate between p53 mutation 
and tumour stage (See Figure 19). Overall the results from this study indicate that p53 is a 
significant driver of oncogenesis in OSCC in both the smoking and non-smoking population. 
It represents a key target in OSCC and many other cancers and this research validates the 
effort spent attempting to control this key driver of oncogenesis. 
 
The next most commonly seen mutation was in NSD1, which was mutated in 33% of the 
participants. The significance of these mutations however is hard to determine. Of the 15 
participants with a NSD1 mutation, only four had mutations, which were not considered a 
silent mutation. Silent mutations were considered the least severe mutation type from the 
GATK analysis, and all silent mutations were only synonymous mutations. From the TCGA 
data set, NSD1 mutations occurred in only 11% of all samples, however in contrast to this 
study, the mutations in NSD1 were more severe. The majority of NSD1 mutations in the 
TCGA dataset performed a silencing function. In the TCGA these type of mutation would 
biologically significant, as NSD1 is a tumour suppressor gene 128. Thus by silencing the 
action of NSD1, oncogenesis would be driven. Thus it is difficult to correlate the NSD1 
mutations seen in this study with the NSD1 mutations seen in the TCGA data.  
 
CDKN2A was one of the more commonly mutated genes in this study (24%). CDKN2A is a 
cell cycle regulator, responsible for the production of tumour suppressor proteins. It has been 
reported that mutations in CDKN2A have been reported more frequently in HPV negative 
tumours, compared with HPV positive tumours 128. Similar to the observations with TP53 and 
HPV induced disease, it is difficult to assess the link between CDKN2A and HPV induced 
disease due the small sample size for HPV positive tumours. Regardless, neither of the HPV 
positive tumours showed CDKN2A mutations, adding some support to this observation from 
the TCGA study. The expression of CDKN2A was then compared to the mutation rate in 
CDKN2A. There wasn’t any link between CDKN2A expression and mutation (See Figure 8). 
Both high (2014079003) and low (2015253001) CDKN2A expression was seen amongst the 
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samples showing CDKN2A mutations in the exome sequencing data. Finally, as shown in 
Figure 19, there was a lack of correlation between CDKN2A mutation rate and the 
demographic details collected. Overall CDKN2A remains likely as a key driver in oncogenic 
process, however the situations that it is more significant driver is unexplained by this study. 
 
Multiple studies on NGS, had classified NOTCH1 as a gene of special interest in head and 
neck carcinoma 107, 110. In these other studies NOTCH1 was reported to be altered in OSCC at 
a rate of 40-54%. In this study’s results, this was not the case. Of the 45 samples tested only 
five (11.1%) had a mutated NOTCH1 gene, indicating that these OSCC samples do not fit 
with previously reported literature.  
 
The third most commonly mutated gene was HUWE1. HUWE1 was mutated in 11 
participants (24.4%). This is of interest as current literature has not reported HUWE1 
mutations as common amongst OSCC or HNC patients. HUWE1 is an E3 ubiquitin ligase, 
which is part of the HECT family153. Its specific role in cancer development is unclear as 
silencing the HUWE1 has been shown to both promote cell survival and cell apoptosis. 
Whilst the biological action of HUWE1 is unclear, it appears that it may play a role in 
binding to p53 and c-MYC153. HUWE1 overexpression has been seen in colorectal, lung and 
breast cancers, however as mentioned, it’s link with HNC is as yet unexplored. Thus the role 
of HUWE1 may need to be further explored, in particular this should be achieved by 
sequencing this region in more depth and additionally increasing the sample size.  
 
Overall the exome sequencing work clarified that the most commonly seen mutation amongst 
head and neck cancer patients is in the TP53 gene. Other commonly mutated genes including 
CDKN2A and NSD1 have been previously reported as common in the literature. However, it 
was interesting to note that NOTCH1 was not a common mutation in our sample group when 
compared with previously reported OSCC populations. Finally, HUWE1 is a gene which was 
found to have significant mutations in this study and further work investigating its role in 
OSCC is needed.   	
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5.0	Conclusions,	Limitations	and	Further	Research	
 
Overall, this research highlights a number of key understandings of the aetiology of oral 
cavity cancer. Firstly, OSCC is a disease which is not commonly due to HPV, with HPV 
presence and induced changes seen in less than 5% of the OSCC samples. Next, through 
next-generation sequencing, this study has found that there is no significant transcriptomal 
difference between the smoking and non-smoking tumours. However, there were trends from 
the WCGNA analysis which may indicate that changes in mTOR and EGF-EGFR signalling 
are more common-place in the smoking population. This knowledge may prove useful for 
further research investigating therapeutic options in these patients. Additionally, RNAseq 
data showed biologically consistent results; more advanced tumours showed higher rates of 
anaerobic metabolism in comparison with less advanced disease. Utilising exome sequencing 
this study determined that the most significant mutation amongst the participants in this study 
was in the TP53 gene. There were several genes which showed relatively high levels of 
mutations and these included NSD1 and CDKN2A. HUWE1 also showed mutations in 24.4% 
of samples, a gene which has previously not been described as a common mutation in OSCC.  
 
Despite these findings there were numerous limitations to this study which may hinder it’s 
applicability. Firstly, this study did not collect matched normal tissue. Whilst exploring 
RNAseq data is relatively straightforward without this matched tissue, exploring the DNA 
exome data was difficult. As mentioned above it required utilising of the data from the 1000 
genomes project as the matched normal tissue to exclude underlying germline mutations. 
Whilst this limited the number of mutations to around 1700 per sample, there is the potential 
that a participant had an unknown germline variance, which would have been reported as a 
mutation in the tumour samples. Conversely, a germline mutation in the 1000 genome project 
data may not have been in that participant’s germline normal tissue, resulting in a potential 
significant mutation being excluded from the report of the somatic mutations. Thus, a 
significant improvement to this study would have been to obtain samples of normal tissue 
from participants. Ideally this would have been the same tissue as the tumour biopsy, for 
example normal tongue tissue if the participant had tongue cancer. This would allow for 
matched analysis with both RNA sequencing as well as DNA exome sequencing. 
Unfortunately, this was not done and was an error in the design of this study.  
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Another significant improvement would be to collect additional demographic data during the 
participant recruitment process. Through exploring the literature, there are several 
demographics which, should this study be repeated, should be collected. These include, but 
are not limited to: 
Alcohol consumption: 
Type and frequency of alcohol consumption. Whilst this study collected the number of 
standard drinks consumed by participants per week, this merely was a snapshot in that 
patient’s drinking behaviour at the time of diagnosis. Information such as type of alcohol 
consumed, especially on the number of drinks with high alcohol content, could prove to be 
significant. Specifically, there are now some reports that high alcohol concentration drinks 
may be directly carcinogenic to mucosal tissue, and thus significant for this research. 
Additionally, participants have reported alcohol consumption at the time of diagnosis, but 
those participants may have had significant higher alcohol consumption in the years leading 
up to diagnosis and this would not have been recorded.  
 
Often collection of the demographic data was performed during a busy head and neck clinic 
by a research experienced nurse. This nurse was often divided between multiple research 
projects, and would be required to consent multiple patients per clinic for a variety of studies. 
Thus, collection of demographic data may have been limited by the time available. These 
specific questions on alcohol consumption, should firstly be designed by those experienced in 
taking thorough alcohol consumption history, namely drug and alcohol physicians. Then this 
information should be collected in a setting separate to the head and neck clinic, such that 
researchers and assistants, are not rushed in taking an accurate and detailed history. 
 
Survival: 
In this study, survival data was not collected. Information regarding survival, was not one of 
the original objectives of the study. However, there is some literature which has explored 
genetic and transcriptomal differences between samples and survival. Survival data should be 
collected as there may be transcriptional and genetic differences which would help explain 
survival differences between participants. This could lead to NGS data being used to help 
predict disease prognosis in HNC patients. The downside of collecting survival data is that 
such a study would be required to run over an extended time frame (at least five years from 
 63 
the collection of the last participant sample) to get a complete understanding of how survival 
differences are linked to transcriptomal and mutational differences between participants.  
 
Ethnicity: 
When using the 1000 genomes project for the matched normal tissue, to exclude underlying 
germline mutations, we assumed all participants were Caucasian. Collection of participant 
ethnicity may also help to identify transcriptomal and genetic differences between 
participants.   
 
The final significant improvement that could be made to this study would be to increase the 
study population. With a total of only 45 participants with tissue of sufficient quality, the 
sample size, and thus the power to detect significant differences between participants was 
limited. Efforts at attempting to maximise the numbers of participants was limited by the 
number of presentations to head and neck clinics in the Brisbane region over the preceding 3 
years of this study. The answer to this problem is that resources need to be combined across 
Australia. There is limited utility in multiple centres across the country repeating the same or 
similar research, however that is the current state of affairs. There are several research centres 
in Australia, which are all performing similar next-generation sequencing work to attempt to 
identify the aetiology of head and neck cancers. Additionally, many are attempting to explore 
future therapeutic options for HNC. The difficulty comes in funding a large collaboration 
between centres, and also agreeing to a set of common goals of the research. Thus the 
difficulties of combining the work of multiple centres is more logistical, rather than scientific. 
Good science should however not be inhibited by logistical or political decisions between 
head and neck centres. The information gathered from a large Australia wide collaboration 
should also investigated the potential of contributing to the data for TCGA, thus allowing for 
an increasing large sample size for the potential to identify statistically significant 
transcriptomal and genetic changes in head and neck cancer tissues. After all, improving 
patient outcomes, through identifying aetiology and developing new therapeutics, should be 
the overarching goal of all OSCC research.  
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Appendix H – DNA Extraction Analysis on Nanodrop 
Sample Concentration (ng/µL) A260/280 
20131550013B 43.9 2.03 
2013218002 36.2 2.06 
2013232002 13.5 2.03 
2013246002 13.4 1.89 
2013255013	 74.9 2.02 
2013262001 58.0 2.06 
2013274001 7.2 1.76 
2013302002 5.5 1.85 
2013315001 142.4 1.58 
2013315002 70.2 1.82 
2013350001 43.9 1.90 
2013350002 38.8 2.02 
2014017001 44.3 1.91 
2014037004 33.0 1.96 
2014079003 24.5 1.94 
2014086001 72.8 2.05 
2014142002 207.7 2.06 
2014142004 65.3 2.02 
2014150001 73.2 1.99 
2014156001 65.6 1.96 
2014156003 74.4 2.00 
2014183001 51.2 114.4 
2014192001 114.4 2.00 
2014199003 92.7 1.96 
2014206001 88.4 1.99 
2014219001 77.3 2.02 
2014230001 45.1 2.02 
2014246001 40.7 2.03 
2014255001 116.8 2.00 
2014262001 85.9 2.06 
2014269001 34.0 1.96 
2014309001 44.6 2.03 
2014338002 125.0 2.04 
2014342001 20.5 1.93 
2014344001 51.2 2.02 
2014345001 83.2 2.06 
2014349001 55.4 2.02 
2015012001 121.9 2.02 
2015036001 40.6 1.96 
2015145001 40.5 1.92 
2015180001 24.5 1.90 
2015194001 99.8 1.99 
2015197001 91.3 1.98 
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2015201001 27.4 1.95 
2015204001 49.7 2.00 
 
Appendix I - DNA Extraction Analysis on Nanodrop following RNAse digestion 
 
Sample Concentration (ng/µL) A260/280 
20131550013B 83.1 1.13 
2013218002 39.9 1.91 
2013232002 24.5 1.94 
2013246002 3.1 1.83 
2013255013	 13.8 1.89 
2013262001 4.3 1.86 
2013274001 1.9 1.93 
2013302002 2.0 1.80 
2013315001 20.7 1.86 
2013315002 20.4 1.88 
2013350001 13.0 1.88 
2013350002 9.7 1.86 
2014017001 14.5 1.87 
2014037004 24.6 1.88 
2014079003 14.1 1.79 
2014086001 11.5 1.87 
2014142002 16.4 1.81 
2014142004 11.5 1.80 
2014150001 13.7 1.84 
2014156001 17.8 1.69 
2014156003 15.0 1.88 
2014183001 7.1 1.88 
2014192001 21.4 1.87 
2014199003 27.2 1.91 
2014206001 18.1 1.86 
2014219001 8.9 1.86 
2014230001 5.0 1.78 
2014246001 7.7 1.75 
2014255001 20.2 1.73 
2014262001 9.1 1.85 
2014269001 6.8 1.80 
2014309001 5.3 1.75 
2014338002 15.5 1.85 
2014342001 4.8 1.58 
2014344001 6.5 1.81 
2014345001 8.7 1.81 
2014349001 10.2 1.86 
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2015012001 15.8 1.84 
2015036001 13.7 1.84 
2015145001 10.1 1.73 
2015180001 9.3 1.81 
2015194001 21.4 1.81 
2015197001 8.8 1.81 
2015201001 7.8 1.80 
2015204001 9.7 1.73 
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Appendix J – Tabulated Results from digene HC2 Testing 
 
Table 6 – digene hc2 High-Risk HPV DNA Test Luminometer Results – Run1 
 
Sample	Number	 Value Ratio to HRC Value 
Average	of	HRC	Tests	(Cut-
Off)	
6850 1.00 
QC	–	Low	Risk	 1418 0.21 
QC	–	High	Risk	 30688 4.48 
20131550013B 2063 0.30 
2013218002 2329 0.34 
2013232002 2321 0.34 
2013246002 3352 0.49 
2013255013	 1349 0.20 
2013262001 1585 0.23 
2013274001 3002 0.44 
2013302002 2703 0.39 
2013315001 1449 0.21 
2013315002 772 0.11 
 
Table 7 – digene hc2 High-Risk HPV DNA Test Luminometer Results – Run 2 
Sample	Number	 Value Ratio to HRC Value 
Average	of	HRC	Tests	(Cut-
Off)	
9166 1.00 
QC	–	Low	Risk	HPV	 2339 0.26 
QC	–	High	Risk	HPV	 30798 3.36 
2013262001 6813 0.743290421 
2013350001 3290 0.358935195 
2013350002 6391 0.697250709 
2014017001 2494 0.272092516 
2014037004 2513 0.274165394 
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Appendix K – Nanodrop Analysis – RNA Extraction 
Sample Concentration (corrected) 
(ng/µL) 
A260/280 
2013155002	
Sample	stored	initially	on	dry	ice.	 
3.0 1.7 
2013155003A	
Sample	initially	stored	in	RNAlater	
23.5	 2.04	
2013162002	
Dry	ice 
5.5	 1.82	
2013162002	
RNAlater	
658.5	 2.09	
2013218002 236.5	 2.09	
2013232002 402.5	 1.81	
2013246002 126.5	 1.61	
2013255013	 668	 2.08	
2013262001 86.5	 2.05	
2013274001 134.5	 1.84	
2013302002 273	 2.04	
2013315001 3	 1.98	
2013315002 1516	 1.98	
2013350001 814	 2.09	
2013350002 145.5	 2.01	
2014017001 2093.5	 1.96	
2014037004	
Initially	in	formalin 
10	 1.56	
2014079003 1058	 1.97	
2014079005	 7.2	 1.72	
2014086001 245	 1.91	
2014142002 562	 1.93	
2014142004 399	 1.96	
2014150001 1181.5	 2.00	
2014156001 1047.5	 1.98	
2014156003 2090	 1.96	
2014183001 352.5	 1.98	
2014192001 2346	 2.03	
2014199003 316.5	 1.99	
2014206001 576.5	 1.99	
2014219001 55	 2.03	
2014230001 821	 1.89	
2014246001 135	 2.01	
2014255001 402.5	 1.96	
2014262001 481.5	 1.93	
2014269001 153.5	 2.03	
2014309001 311	 2.04	
2014338002 537	 1.97	
2014342001 85.5	 2.03	
2014344001 104.5	 1.95	
2014345001 171	 1.97	
2015012001 1361.5	 1.96	
2015036001 66	 1.99	
2015145001 386.5	 1.96	
2015180001 25.5	 2.02	
2015194001 954	 1.95	
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2015197001 603.5	 1.96	
2015201001 74	 2.07	
2015204001 409.5	 1.96	
2015253001	 721	 1.92	
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